Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Amneal (AMRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
This week we saw the Verrica Pharmaceuticals Inc. ( NASDAQ:VRCA ) share price climb by 11%. But over the last three...
WEST CHESTER, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica’s President & Chief Executive Officer, will present at the upcoming 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from April 8-11, 2024. Event details:Date: Tuesday, April 9, 2024Time: 2:15 pm ET Participa
NCE status provides a minimum of five years of regulatory exclusivity The Company’s U.S. patents and pending patent applications related to YCANTH™ are projected to expire between 2034 and 2041, excluding any patent term adjustment or patent term extension WEST CHESTER, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today
We feel now is a pretty good time to analyse Verrica Pharmaceuticals Inc.'s ( NASDAQ:VRCA ) business as it appears the...
Verrica Pharmaceuticals ( NASDAQ:VRCA ) Full Year 2023 Results Key Financial Results Net loss: US$67.0m (loss widened...
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript February 29, 2024 Verrica Pharmaceuticals Inc. misses on earnings expectations. Reported EPS is $-0.53 EPS, expectations were $-0.47. Verrica Pharmaceuticals Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
Revenue Growth and Pipeline Advancements Mark Key Developments
– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30 am ET – WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth qua
WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that they will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference, which will be held in Boston, Massachusetts. Event details:Date: Tuesday, March 5, 2024Time: 10:30am ETLocation: Boston, MA Participants may access a l